Prophylactic first-line antibiotics reduce infectious fever and shorten hospital stay during chemotherapy-induced agranulocytosis in childhood acute myeloid leukemia

Acta Haematologica

Volumn 132, Issue 1, 2014, Pages 112-117

  Feng, Xiaoqin ^a   Ruan, Yongsheng ^a   He, Yuelin ^a   Zhang, Yuming ^a   Wu, Xuedong ^a   Liu, Huayin ^a   Liu, Xuan ^a   He, Lan ^a   Li, Chunfu ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Antibiotics; Child; Leukemia; Myeloid; Prophylaxis

Indexed keywords

CEFEPIME; CYTARABINE; ETOPOSIDE; IDARUBICIN; MITOXANTRONE; PIPERACILLIN DERIVATIVE; TIOGUANINE; VANCOMYCIN; CARBAPENEM; PIPERACILLIN PLUS TAZOBACTAM; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TEICOPLANIN; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; AGRANULOCYTOSIS; ARTICLE; BACTERIAL INFECTION; BRONCHITIS; CANCER COMBINATION CHEMOTHERAPY; CATHETER INFECTION; CHEMOTHERAPY INDUCED AGRANULOCYTOSIS; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FEVER; GASTROINTESTINAL INFECTION; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; HOSPITALIZATION; HUMAN; INCIDENCE; INFECTIOUS FEVER; LUNG INFECTION; MALE; MOUTH INFECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; SKIN INFECTION; UPPER RESPIRATORY TRACT INFECTION; ANTIBIOTIC PROPHYLAXIS; CANCER CHEMOTHERAPY; CLINICAL PROTOCOL; DRUG SUBSTITUTION; INFECTION PREVENTION; LENGTH OF STAY; MULTIPLE CYCLE TREATMENT; NEUTROPHIL COUNT;

ADOLESCENT; AGRANULOCYTOSIS; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CEPHALOSPORINS; CHILD; CHILD, PRESCHOOL; FEMALE; FEVER; HUMANS; INFECTION CONTROL; LENGTH OF STAY; LEUKEMIA, MYELOID, ACUTE; MALE; PENICILLANIC ACID; PIPERACILLIN; PROSPECTIVE STUDIES; VANCOMYCIN;

EID: 84893653929     PISSN: 00015792     EISSN: 14219662     Source Type: Journal    
DOI: 10.1159/000356626     Document Type: Article

References (22)

1. Hasle H, Abrahamsson J, Forestier E, Ha SY, Heldrup J, Jahnukainen K, Jónsson ÓG, Lausen B, Palle J, Zeller B, Nordic Society of Paediatric Haematology and Oncology (NOPHO): Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004. Blood 2004; 120: 978-984.
2. Loken MR, Alonzo TA, Pardo L, Gerbing RB, Raimondi SC, Hirsch BA, Ho PA, Franklin J, Cooper TM, Gamis AS, Meshinchi S: Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group. Blood 2012; 120: 1581-1588.
3. Rubnitz JE, Inaba H, Dahl G, Ribeiro RC, Bowman WP, Taub J, Pounds S, Razzouk BI, Lacayo NJ, Cao X, Meshinchi S, Degar B, Airewele G, Raimondi SC, Onciu M, Coustan-Smith E, Downing JR, Leung W, Pui CH, Campana D: Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol 2010; 11: 543-552.
4. Gamis AS, Howells WB, DeSwarte-Wallace J, Feusner JH, Buckley JD, Woods WG: Alpha hemolytic streptococcal infection during intensive treatment for acute myeloid leukemia: a report from the Children's Cancer Group study CCG-2891. J Clin Oncol 2000; 18: 1845-1855.
5. Husain E, Whitehead S, Castell A, Thomas EE, Speert DP: Viridans streptococci bacteremia in children with malignancy: relevance of species identification and penicillin susceptibility. Pediatr Infect Dis J 2005; 24: 563-566.
6. Sotiropoulos SV, Jackson MA, Woods GM, Hicks RA, Cullen J, Freeman AI: Alpha-streptococcal septicemia in leukemic children treated with continuous or large dosage intermittent cytosine arabinoside. Pediatr Infect Dis J 1989; 8: 755-758.
7. Weisman SJ, Scoopo FJ, Johnson GM, Altman AJ, Quinn JJ: Septicemia in pediatric oncology patients: the significance of viridans streptococcal infections. J Clin Oncol 1990; 8: 453-459.
8. Choudhry VP, Krishnamurthy L, Arya LS, Desai N, Pati H: Causes of mortality in children with acute lymphocytic leukemia. Indian Pediatr 1992; 29: 709-713.
9. Sheng Q, Chen TX, Zhang Q, Zhao HJ, Yuan XJ, Yao HY: Analysis on the cause of treatment related death in childhood leukemia. J Clin Ped 2005; 23: 524-544.
10. Pillon M, Di Tullio MT, Garaventa A, Cesaro S, Putti MC, Favre C, Lippi A, Surico G, Di Cataldo A, D'Amore E, Zanesco L, Rosolen A: Long-term results of the first Italian Association of Pediatric Hematology and Oncology protocol for the treatment of pediatric B-cell non-Hodgkin lymphoma (AIEOP LNH92). Cancer 2004; 101: 385-394.
11. Molgaard-Hansen L, Möttönen M, Glosli H, Jónmundsson GK, Abrahamsson J, Hasle H: Early and treatment-related deaths in childhood acute myeloid leukaemia in the Nordic countries: 1984-2003. Br J Haematol 2010; 151: 447-459.
12. Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G, Allione B, D'Antonio D, Buelli M, Nosari AM, Cilloni D, Zuffa E, Cantaffa R, Specchia G, Amadori S, Fabbiano F, Deliliers GL, Lauria F, Foà R, Del Favero A, Gruppo Italiano Malattie Ematologiche dellAdulto (GIMEMA) Infection Program: Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 2005; 353: 977-987.
13. Gafter-Gvili A, Fraser A, Paul M, Leibovici L: Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 2005; 142: 979-995.
14. Leibovici L, Paul M, Cullen M, Bucaneve G, Gafter-Gvili A, Fraser A, Kern WV: Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions. Cancer 2006; 107: 1743-1751.
15. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR, Infectious Diseases Society of America: Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011; 52:e56-e93.
16. Meunier F, Lukan C: The First European Conference on Infections in Leukaemia-ECIL1: a current perspective. Eur J Cancer 2008; 44: 2112-2117.
17. Segal BH, Freifeld AG, Baden LR, Brown AE, Casper C, Dubberke E, Gelfand M, Greene JN, Ison MG, Ito JI, Karp JE, Kaul DR, King E, Mackler E, Marcucci G, Montoya JG, Engemann AM, Rolston K, The AS: Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw 2008; 6: 122-174.
18. Castagnola E, Haupt R, Micozzi A, Caviglia I, Testi AM, Giona F, Parodi S, Girmenia C: Differences in the proportions of fluoroquinolone-resistant Gram-negative bacteria isolated from bacteraemic children with cancer in two Italian centres. Clin Microbiol Infect 2005; 11: 505-507.
19. Ito JI, Tegtmeier BR, O'Donnell MR: Antibacterial prophylaxis in patients with cancer and neutropenia. N Engl J Med 2006; 354: 90-94.
20. Kern WV, Klose K, Jellen-Ritter AS, Oethinger M, Bohnert J, Kern P, Reuter S, von Baum H, Marre R: Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia. Eur J Clin Microbiol Infect Dis 2005; 24: 111-118.
21. Kurt B, Flynn P, Shenep JL, Pounds S, Lensing S, Ribeiro RC, Pui CH, Razzouk BI, Rubnitz JE: Prophylactic antibiotics reduce morbidity due to septicemia during intensive treatment for pediatric acute myeloid leukemia. Cancer 2008; 113: 376-382.
22. Yousef AA, Fryer CJ, Chedid FD, Abbas AA, Felimban SK, Khattab TM: A pilot study of prophylactic ciprofloxacin during delayed intensification in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2004; 43: 637-643.